Does the media prefer AVCT or OXB?

In the previous week, Oxford Biomedica had 2 more articles in the media than Avacta Group. MarketBeat recorded 3 mentions for Oxford Biomedica and 1 mentions for Avacta Group. Avacta Group's average media sentiment score of 0.67 beat Oxford Biomedica's score of -0.44 indicating that Avacta Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avacta Group 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oxford Biomedica 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate SLN or AVCT?

Avacta Group has a consensus price target of GBX 99, suggesting a potential upside of 47.76%. Given Avacta Group's stronger consensus rating and higher probable upside, analysts clearly believe Avacta Group is more favorable than Silence Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Silence Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Avacta Group 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Do analysts recommend AVCT or HZD?

Avacta Group currently has a consensus target price of GBX 99, indicating a potential upside of 47.76%. Given Avacta Group's stronger consensus rating and higher possible upside, equities research analysts clearly believe Avacta Group is more favorable than Horizon Discovery Group plc (HZD.L). Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avacta Group 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Horizon Discovery Group plc (HZD.L) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Does the media favor PRTC or AVCT?

In the previous week, PureTech Health and PureTech Health both had 1 articles in the media. PureTech Health's average media sentiment score of 1.11 beat Avacta Group's score of 0.67 indicating that PureTech Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PureTech Health 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Avacta Group 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer ARIX or AVCT?

Avacta Group has a consensus target price of GBX 99, suggesting a potential upside of 47.76%. Given Avacta Group's stronger consensus rating and higher probable upside, analysts plainly believe Avacta Group is more favorable than Arix Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arix Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Avacta Group 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Avacta Group (AVCT) Competitors

GBX 67 -1.50 (-2.19%)

As of 08/21/2026 12:28 PM Eastern

Compare

AVCT vs. OXB, SLN, HZD, PRTC, and ARIX

Should you buy Avacta Group stock or one of its competitors? Avacta Group's main competitors and comparable companies include Oxford Biomedica (OXB), Silence Therapeutics (SLN), Horizon Discovery Group plc (HZD.L) (HZD), PureTech Health (PRTC), and Arix Bioscience (ARIX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Avacta Group compare to Oxford Biomedica?

Avacta Group (LON:AVCT) and Oxford Biomedica (LON:OXB) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

3.1% of Avacta Group shares are held by institutional investors. Comparatively, 32.4% of Oxford Biomedica shares are held by institutional investors. 47.7% of Avacta Group shares are held by insiders. Comparatively, 25.8% of Oxford Biomedica shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Oxford Biomedica had 2 more articles in the media than Avacta Group. MarketBeat recorded 3 mentions for Oxford Biomedica and 1 mentions for Avacta Group. Avacta Group's average media sentiment score of 0.67 beat Oxford Biomedica's score of -0.44 indicating that Avacta Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avacta Group	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oxford Biomedica	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Avacta Group has a beta of 1.12, indicating that its stock price is 12% more volatile than the broader market. Comparatively, Oxford Biomedica has a beta of 1.1, indicating that its stock price is 10% more volatile than the broader market.

Avacta Group currently has a consensus price target of GBX 99, suggesting a potential upside of 47.76%. Oxford Biomedica has a consensus price target of GBX 580.85, suggesting a potential upside of 11.13%. Given Avacta Group's stronger consensus rating and higher possible upside, equities analysts plainly believe Avacta Group is more favorable than Oxford Biomedica.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avacta Group	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Oxford Biomedica	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80

Oxford Biomedica has a net margin of -17.85% compared to Avacta Group's net margin of -33,961.06%. Oxford Biomedica's return on equity of -48.56% beat Avacta Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avacta Group	-33,961.06%	-2,929.47%	-21.80%
Oxford Biomedica	-17.85%	-48.56%	-12.67%

Avacta Group has higher earnings, but lower revenue than Oxford Biomedica. Oxford Biomedica is trading at a lower price-to-earnings ratio than Avacta Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avacta Group	£113K	2,778.12	-£30.08M	-£9.66	N/A
Oxford Biomedica	£168.74M	3.75	-£143.51M	-£26.92	N/A

Summary

Avacta Group beats Oxford Biomedica on 9 of the 16 factors compared between the two stocks.

How does Avacta Group compare to Silence Therapeutics?

Silence Therapeutics (LON:SLN) and Avacta Group (LON:AVCT) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, risk, media sentiment, valuation, dividends and profitability.

3.1% of Avacta Group shares are held by institutional investors. 47.7% of Avacta Group shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Silence Therapeutics has a net margin of 0.00% compared to Avacta Group's net margin of -33,961.06%. Silence Therapeutics' return on equity of 0.00% beat Avacta Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silence Therapeutics	N/A	N/A	N/A
Avacta Group	-33,961.06%	-2,929.47%	-21.80%

Silence Therapeutics has higher revenue and earnings than Avacta Group. Avacta Group is trading at a lower price-to-earnings ratio than Silence Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silence Therapeutics	£11.35M	0.00	N/A	-£48.60	N/A
Avacta Group	£113K	2,778.12	-£30.08M	-£9.66	N/A

Avacta Group has a consensus price target of GBX 99, suggesting a potential upside of 47.76%. Given Avacta Group's stronger consensus rating and higher probable upside, analysts clearly believe Avacta Group is more favorable than Silence Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silence Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Avacta Group	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

In the previous week, Avacta Group had 1 more articles in the media than Silence Therapeutics. MarketBeat recorded 1 mentions for Avacta Group and 0 mentions for Silence Therapeutics. Avacta Group's average media sentiment score of 0.67 beat Silence Therapeutics' score of 0.00 indicating that Avacta Group is being referred to more favorably in the news media.

Company	Overall Sentiment
Silence Therapeutics	Neutral
Avacta Group	Positive

Summary

Avacta Group beats Silence Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Avacta Group compare to Horizon Discovery Group plc (HZD.L)?

Avacta Group (LON:AVCT) and Horizon Discovery Group plc (HZD.L) (LON:HZD) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, valuation, media sentiment, analyst recommendations, institutional ownership and risk.

Horizon Discovery Group plc (HZD.L) has higher revenue and earnings than Avacta Group. Avacta Group is trading at a lower price-to-earnings ratio than Horizon Discovery Group plc (HZD.L), indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avacta Group	£113K	2,778.12	-£30.08M	-£9.66	N/A
Horizon Discovery Group plc (HZD.L)	£54.63M	0.00	N/A	-£5.50	N/A

Avacta Group currently has a consensus target price of GBX 99, indicating a potential upside of 47.76%. Given Avacta Group's stronger consensus rating and higher possible upside, equities research analysts clearly believe Avacta Group is more favorable than Horizon Discovery Group plc (HZD.L).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avacta Group	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Horizon Discovery Group plc (HZD.L)	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Horizon Discovery Group plc (HZD.L) has a net margin of 0.00% compared to Avacta Group's net margin of -33,961.06%. Horizon Discovery Group plc (HZD.L)'s return on equity of 0.00% beat Avacta Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avacta Group	-33,961.06%	-2,929.47%	-21.80%
Horizon Discovery Group plc (HZD.L)	N/A	N/A	N/A

In the previous week, Avacta Group had 1 more articles in the media than Horizon Discovery Group plc (HZD.L). MarketBeat recorded 1 mentions for Avacta Group and 0 mentions for Horizon Discovery Group plc (HZD.L). Avacta Group's average media sentiment score of 0.67 beat Horizon Discovery Group plc (HZD.L)'s score of 0.00 indicating that Avacta Group is being referred to more favorably in the media.

Company	Overall Sentiment
Avacta Group	Positive
Horizon Discovery Group plc (HZD.L)	Neutral

3.1% of Avacta Group shares are owned by institutional investors. 47.7% of Avacta Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Avacta Group beats Horizon Discovery Group plc (HZD.L) on 8 of the 13 factors compared between the two stocks.

How does Avacta Group compare to PureTech Health?

PureTech Health (LON:PRTC) and Avacta Group (LON:AVCT) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, media sentiment, earnings, institutional ownership, risk, analyst recommendations and valuation.

Avacta Group has lower revenue, but higher earnings than PureTech Health. Avacta Group is trading at a lower price-to-earnings ratio than PureTech Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PureTech Health	£4.66M	61.44	-£91.86M	-£46.00	N/A
Avacta Group	£113K	2,778.12	-£30.08M	-£9.66	N/A

32.5% of PureTech Health shares are held by institutional investors. Comparatively, 3.1% of Avacta Group shares are held by institutional investors. 13.4% of PureTech Health shares are held by insiders. Comparatively, 47.7% of Avacta Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

PureTech Health has a net margin of -2,355.32% compared to Avacta Group's net margin of -33,961.06%. PureTech Health's return on equity of -31.98% beat Avacta Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PureTech Health	-2,355.32%	-31.98%	-13.39%
Avacta Group	-33,961.06%	-2,929.47%	-21.80%

PureTech Health has a beta of 0.771, meaning that its stock price is 23% less volatile than the broader market. Comparatively, Avacta Group has a beta of 1.12, meaning that its stock price is 12% more volatile than the broader market.

In the previous week, PureTech Health and PureTech Health both had 1 articles in the media. PureTech Health's average media sentiment score of 1.11 beat Avacta Group's score of 0.67 indicating that PureTech Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PureTech Health	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Avacta Group	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

PureTech Health currently has a consensus target price of GBX 508, suggesting a potential upside of 331.97%. Avacta Group has a consensus target price of GBX 99, suggesting a potential upside of 47.76%. Given PureTech Health's higher possible upside, equities research analysts clearly believe PureTech Health is more favorable than Avacta Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PureTech Health	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Avacta Group	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

PureTech Health beats Avacta Group on 8 of the 13 factors compared between the two stocks.

How does Avacta Group compare to Arix Bioscience?

Arix Bioscience (LON:ARIX) and Avacta Group (LON:AVCT) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, valuation, earnings, institutional ownership, risk, analyst recommendations and profitability.

Arix Bioscience has higher revenue and earnings than Avacta Group. Avacta Group is trading at a lower price-to-earnings ratio than Arix Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arix Bioscience	£14.16M	0.00	£14.96M	£0.11	N/A
Avacta Group	£113K	2,778.12	-£30.08M	-£9.66	N/A

41.3% of Arix Bioscience shares are held by institutional investors. Comparatively, 3.1% of Avacta Group shares are held by institutional investors. 20.7% of Arix Bioscience shares are held by insiders. Comparatively, 47.7% of Avacta Group shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Arix Bioscience has a beta of 1.05, meaning that its share price is 5% more volatile than the broader market. Comparatively, Avacta Group has a beta of 1.12, meaning that its share price is 12% more volatile than the broader market.

In the previous week, Avacta Group had 1 more articles in the media than Arix Bioscience. MarketBeat recorded 1 mentions for Avacta Group and 0 mentions for Arix Bioscience. Avacta Group's average media sentiment score of 0.67 beat Arix Bioscience's score of 0.00 indicating that Avacta Group is being referred to more favorably in the news media.

Company	Overall Sentiment
Arix Bioscience	Neutral
Avacta Group	Positive

Arix Bioscience has a net margin of 105.64% compared to Avacta Group's net margin of -33,961.06%. Arix Bioscience's return on equity of 6.41% beat Avacta Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arix Bioscience	105.64%	6.41%	2.18%
Avacta Group	-33,961.06%	-2,929.47%	-21.80%

Avacta Group has a consensus target price of GBX 99, suggesting a potential upside of 47.76%. Given Avacta Group's stronger consensus rating and higher probable upside, analysts plainly believe Avacta Group is more favorable than Arix Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arix Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Avacta Group	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Arix Bioscience beats Avacta Group on 8 of the 15 factors compared between the two stocks.

Get Avacta Group News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AVCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AVCT vs. The Competition

Export

Metric	Avacta Group	Biotechnology Industry	Healthcare Sector	LON Exchange
Market Cap	£318.61M	£4.01B	£7.38B	£2.54B
Dividend Yield	3.97%	3.64%	2.53%	6.17%
P/E Ratio	-6.94	11.62	272.60	367.57
Price / Sales	2,778.12	1,334.59	623.32	83,481.74
Price / Cash	15.00	105.14	78.62	27.89
Price / Book	4.55	16.80	13.05	7.19
Net Income	-£30.08M	-£12.50M	£3.47B	£5.89B
7 Day Performance	3.67%	3.29%	2.09%	0.30%
1 Month Performance	-2.90%	8.23%	6.63%	3.31%
1 Year Performance	37.99%	55.05%	25.01%	22.13%

Avacta Group Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AVCT Avacta Group	2.4394 of 5 stars	GBX 67 -2.2%	GBX 99 +47.8%	+38.0%	£318.61M	£113K	N/A	120	News Coverage
OXB Oxford Biomedica	1.5284 of 5 stars	GBX 487 -0.1%	GBX 621.85 +27.7%	-2.5%	£589.45M	£168.74M	N/A	891	News Coverage Analyst Downgrade
SLN Silence Therapeutics	N/A	N/A	N/A	N/A	£480.35M	£11.35M	N/A	100	High Trading Volume
HZD Horizon Discovery Group plc (HZD.L)	N/A	N/A	N/A	N/A	£302.98M	£54.63M	N/A	416
PRTC PureTech Health	3.6134 of 5 stars	GBX 119.69 -2.1%	GBX 508 +324.4%	-15.2%	£291.36M	£4.66M	N/A	300

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:AVCT) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Avacta Group (AVCT) Competitors

AVCT vs. OXB, SLN, HZD, PRTC, and ARIX

How does Avacta Group compare to Oxford Biomedica?

Summary

How does Avacta Group compare to Silence Therapeutics?

Summary

How does Avacta Group compare to Horizon Discovery Group plc (HZD.L)?

Summary

How does Avacta Group compare to PureTech Health?

Summary

How does Avacta Group compare to Arix Bioscience?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVCT vs. The Competition

Avacta Group Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Avacta Group (AVCT) Competitors

AVCT vs. OXB, SLN, HZD, PRTC, and ARIX

How does Avacta Group compare to Oxford Biomedica?

Do insiders and institutionals hold more shares of AVCT or OXB?

Does the media prefer AVCT or OXB?

Which has more volatility & risk, AVCT or OXB?

Do analysts rate AVCT or OXB?

Is AVCT or OXB more profitable?

Which has stronger valuation and earnings, AVCT or OXB?

Summary

How does Avacta Group compare to Silence Therapeutics?

Do insiders & institutionals believe in SLN or AVCT?

Is SLN or AVCT more profitable?

Which has stronger earnings and valuation, SLN or AVCT?

Do analysts rate SLN or AVCT?

Does the media prefer SLN or AVCT?

Summary

How does Avacta Group compare to Horizon Discovery Group plc (HZD.L)?

Which has preferable earnings & valuation, AVCT or HZD?

Do analysts recommend AVCT or HZD?

Is AVCT or HZD more profitable?

Does the media favor AVCT or HZD?

Do institutionals & insiders have more ownership in AVCT or HZD?

Summary

How does Avacta Group compare to PureTech Health?

Which has higher valuation & earnings, PRTC or AVCT?

Do institutionals & insiders hold more shares of PRTC or AVCT?

Is PRTC or AVCT more profitable?

Which has more volatility and risk, PRTC or AVCT?

Does the media favor PRTC or AVCT?

Do analysts prefer PRTC or AVCT?

Summary

How does Avacta Group compare to Arix Bioscience?

Which has stronger earnings & valuation, ARIX or AVCT?

Do insiders and institutionals believe in ARIX or AVCT?

Which has more risk and volatility, ARIX or AVCT?

Does the media favor ARIX or AVCT?

Is ARIX or AVCT more profitable?

Do analysts prefer ARIX or AVCT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVCT vs. The Competition

Avacta Group Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools